Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy

Journal of Immunotherapy

Volumn 27, Issue 4, 2004, Pages 265-272

  Shimizu, Keiji ^a   Kuriyama, Hideyuki ^a   Kjaergaard, Jorgen ^a   Lee, Walter ^a   Tanaka, Hiroshi ^a   Shu, Suyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Dendritic cell tumor hybrids; Electrofusion; Vaccination

Indexed keywords

BETA GALACTOSIDE; FLT3 LIGAND; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 12; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CANCER GRAFT; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CYTOKINE PRODUCTION; FEMALE; HYBRID CELL; IMMUNOSTIMULATION; INTERFERON PRODUCTION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 3042600552     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200407000-00002     Document Type: Article

References (33)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
2. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer. 2001;94:459-473.
3. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with GM-CSF. J Exp Med. 1992;176:1693-1702.
4. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996; 183:87-97.
5. Specht JM, Wang G, Do MT, et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary tumor nodules. J Exp Med. 1997;186:1213-1221.
6. Paglia P, Chiodoni C, Rodolfo M, et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med. 1996;183:317-322.
7. Renkvist N, Castelli C, Robbins PF, et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 2001;50:3-15.
8. Strome SE, Voss S, Wilcox R, et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 2002;62:1884-1889.
9. Kotera Y, Shimizu K, Mulé JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 2001;61:8105-8109.
10. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001;7:297-303.
11. Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3:558-561.
12. Lespagnard L, Mettens P, Verheyden AM, et al. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer. 1998;76:250-258.
13. Akasaki Y, Kikuchi T, Homma S, et al. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother. 2001;24:106-113.
14. Gong J, Nikrui N, Chen D, et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol. 2000;165:1705-1711.
15. Li J, Holmes LM, Franek KJ, et al. Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother. 2001;50:456-462.
16. Tanaka Y, Koido S, Chen D, et al. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUCI transgenic mice. Clin Immunol. 2001;101:192-200.
17. Melcher A, Todryk S, Hardwick N, et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med. 1998;4:581-587.
18. Hayashi T, Tanaka H, Tanaka J, et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol. 2002;104:14-20.
19. Tanaka H, Shimizu K, Hayashi T, et al. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol. 2002;220:1-12.
20. Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol. 2003;225: 65-74.
21. Parkhurst MR, DePan C, Riley JP, et al. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol. 2003;170: 5317-5325.
22. b-restricted CTL epitope of β-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods. 1997;12:117-123.
23. Lutz MB, Kukutsch N, Ogilvie ALJ, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77-92.
24. Maraskovsy E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996;184:1953-1962.
25. Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol. 1979;97:587-600.
26. Zimmerman U, Vienken J. Electric field-induced cell-to-cell fusion. J Membr Biol. 1982;67:165-182.
27. White KL. Electrofusion of mammalian cells. In: Nickoloff JA, ed. Methods in Molecular Biology. Clifton, NJ: Humana Press, 1995:283-293.
28. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol. 1991;147:729-737.
29. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol. 2000;20:17-56.
30. + T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression. J Immunol. 2000;165:5738-5749.
31. Nestle F, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4: 328-332.
32. Thurner B, Haendle I, Roder C, et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some tumor nodules in advanced stage IV melanoma. J Exp Med. 1999;190:1669-1678.
33. Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol. 1999;162:168-175.